Trial Profile
A Real-world, retrospective study of efficacy and safety outcomes of panobinostat in patients with penta- and quad-refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 09 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology